Contera Pharma, a subsidiary of Bukwang Pharmaceutical (Bukwang), announced on December 19 that it recently held an inauguration ceremony for a new laboratory with a state-of-the-art laboratory at the DTU Science Park Laboratory in Hörsholm, north of Copenhagen, Denmark.
The opening ceremony started with a speech by Dr. Thomas Sager, the CEO, followed by a tour of the laboratory explaining the new research facilities, and the company had time to explain its R&D capabilities and future directions.
At this event, more than 50 people, including executives and employees of global companies such as Bukwang, OCI, and Mirae Asset Securities, the leading IPO manager, Lundbeck and Roche, gathered to celebrate the establishment of a new research center.
Contera Pharma is a Danish bio venture specializing in central nervous disease treatment, and Bukwang Pharmaceutical acquired it as a 100% subsidiary in 2014.
Contera Pharma will begin laying the groundwork for the company's enduring future growth with the addition of new management at the end of 2020.
The company developed a new drug discovery platform, NOVA, and began developing treatments for incurable and rare neurological diseases for which there is no cure. Since the launch of the platform, it has been active in R&D by deriving five new programs so far.
Contera Pharma has several pipelines, including JM-010 for Parkinson's disease-related dyskinesia. Pipeline has already been recognized for its value of 200 billion won and has attracted more than 50 billion won in investment in Series B.
Meanwhile, the company moved its research center and headquarters to DTU Science Park, where several bio venture companies are located.
